Mizoribine Versus Mycophenolate Mofetil after living donor kidney transplantation for Gastrointestinal Symptoms: a retrospective study in China

Trial Profile

Mizoribine Versus Mycophenolate Mofetil after living donor kidney transplantation for Gastrointestinal Symptoms: a retrospective study in China

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Mizoribine (Primary) ; Mycophenolate mofetil (Primary) ; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jan 2017 Results published in the Transplantation Proceedings
    • 27 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top